Multiple Sclerosis Clinical Trial

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity

Summary

Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe. Common causes of spasticity include cerebral palsy, traumatic brain injury, multiple sclerosis, spinal cord injury, and stroke. This study will assess how safe and effective ABBV-950 is in treating upper limb spasticity in adult post-stroke participants. Adverse events and change in symptoms will be assessed.

ABBV-950 in an investigational drug being developed for treating spasticity. This study is conducted in 2 parts. In Part 1, participants are assigned to receive different doses of ABBV-950 or placebo. There is 1 in 4 chance that participants will be assigned to receive placebo. In Part 2, participants will be randomly assigned to receive BOTOX, ABBV-950, or placebo. There is 1 in 5 chance for participants to receive placebo. Approximately 297 adult post-stroke participants with upper limb spasticity will be enrolled at approximately 50 sites in the United States.

In Part 1, participants will receive intramuscular (IM) injections of ABBV-950 or placebo on Day 1. In Part 2, participants will receive IM injections of BOTOX, ABBV-950, or placebo on Day 1. All participants will be followed for 24 weeks.

There may be higher treatment burden for participants in this trial compared to the standard of care. Participants will attend regular clinic visits during the study. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of upper limb spasticity due to stroke, with most recent stroke occurring at least 12 weeks prior to the Screening visit.
Modified Ashworth Scale-Bohannon (MAS-B) score of >= 3 in the wrist flexors, and a score of >= 1+ in the finger flexors and MAS-B score of >= 2 elbow flexors at both Screening and Visit 2 (Baseline).

Exclusion Criteria:

Additional strokes in the 12 weeks preceding the most recent stroke and in the opinion of the investigator, is not at significant risk of experiencing another stroke during the study period.
Spasticity in the contralateral upper limb that requires treatment.
Presence of fixed contractures in muscles of wrist, elbow, fingers.
Botulinum toxin treatment of any serotype in the 20 weeks prior to Day for upper limb spasticity and in the 12 weeks prior to Day 1 for any indication other than upper limb spasticity.
Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months.
Injection of corticosteroids or anesthetics in the study limb within 12 weeks.
Casting of the upper limbs within 12 weeks.
Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 1

Estimated Enrollment:

297

Study ID:

NCT05956509

Recruitment Status:

Active, not recruiting

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

North County Neurology Associates /ID# 256333
Carlsbad California, 92011, United States
Rancho Los Amigos National Rehabilitation center /ID# 255335
Downey California, 90242, United States
Neuro Pain Medical Center /ID# 256036
Fresno California, 93710, United States
New England Institute for Clinical Research /ID# 255020
Stamford Connecticut, 06905, United States
MedStar National Rehabilitation Hospital /ID# 255630
Washington District of Columbia, 20010, United States
JEM Research Institute /ID# 258782
Lake Worth Florida, 33462, United States
Kansas Institute of Research /ID# 254998
Overland Park Kansas, 66211, United States
University of Missouri Hospital /ID# 255310
Columbia Missouri, 65212, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 1

Estimated Enrollment:

297

Study ID:

NCT05956509

Recruitment Status:

Active, not recruiting

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.